Table 1 General information for the APL patients.
From: Analysis of early death in critically ill patients with acute promyelocytic leukaemia in the HICU
Variable | Survivor (n = 17) | Nonsurvivor (n = 27) | P |
|---|---|---|---|
Gender, no (%) | |||
Female | 9 (20.45) | 19 (43.18) | 0.242 |
Male | 8 (18.18) | 8 (18.18) | |
Age, years, median (IQR) | 49 (27, 58.5) | 46 (36, 55) | 0.893 |
Comorbidity, No (%) | |||
Diabetes | 4 (9.09) | 1 (2.27) | 0.065 |
CHD | 3 (6.81) | 1 (2.27) | 0.282 |
Hypertension | 2 (9.09) | 1 (2.27) | 0.549 |
Peripheral blood count, median (IQR) | |||
WBC, × 109/L | 5.88 (1.39, 16.70) | 36.95 (7.11, 92.38) | 0.004 |
HGB, g/L | 61 (60, 62) | 84 (65, 84) | 0.990 |
PLT, × 109/L | 15 (6.5, 49.5) | 19 (11, 31) | 0.745 |
Coagulation indices, median (IQR) | |||
PT, s | 13.3 (12.3, 15.35) | 16.5 (14.0, 19.0) | 0.002 |
FIB, g/L | 2.0 (1.18, 4.14) | 1.39 (0.69, 2.13) | 0.022 |
DD, mg/L | 17.02 (3.76, 36.53) | 25.84 (9.27, 39.74) | 0.206 |
Creatinine, µmol/L, median (IQR) | 53 (43.2, 72.3) | 71.7 (56.8, 122.2) | 0.037 |
Induction therapy | 17 (41.46) | 24 (58.53) | |
ATO + CMT, No (%) | 3 (17.64) | 14 (82.35) | 0.012 |
ATO, No (%) | 14 (58.33) | 10 (41.66) | |
Induction time, median (IQR) | 31 (28, 32) | 7 (4, 32) | < 0.001 |
Sanz score, No (%) | |||
High-risk patients in ATO + CMT group | 2 (11.76) | 11 (64.70) | 0.659 |
Standard-risk patients in ATO + CMT group | 1 (5.88) | 3 (17.64) | |
High-risk patients in ATO group | 4 (16.66) | 3 (12.5) | 0.643 |
Standard-risk patients in ATO group | 10 (41.66) | 7 (29.16) | |
HICU treatment | |||
IMV, No (%) | 0 | 20 (45.45) | < 0.001 |
CRRT, No (%) | 2 (4.54) | 0 | 0.144 |
Length of stay in HICU, median (IQR) | 4 (2, 10.5) | 2 (1, 6) | 0.096 |
